Regulations.gov document
Reference 17 - Expedited Programs for Serious Conditions - Drugs and Biologics Guidance…
Supporting & Related Material · FDA-2018-D-2238 · posted Jan 30, 2020
Key facts
| Document ID | FDA-2018-D-2238-0053 |
|---|---|
| Title | Reference 17 - Expedited Programs for Serious Conditions - Drugs and Biologics Guidance for Industry re Human Gene Therapy for Hemophilia; Guidance for Industry |
| Document type | Supporting & Related Material |
| Subtype | Background Material |
| Agency | FDA |
| Docket | FDA-2018-D-2238 |
| Posted | Jan 30, 2020 |
At a glance
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: